Institution Directory

Clinical trials at Duke University Medical Center

Sites in Durham, NC

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1500

Shown on this page

Current sort

Live official records

Conditions: End Stage Kidney Disease
Interventions: Biorepository; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stroke, Arm Weakness as a Consequence of Stroke, Upper Extremity Hemiparesis, Upper Extremity Impairments, Upper Extremity Weakness
Interventions: Low intensity focused ultrasound stimulation; Device
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: CXCR2 as a biomarker; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more

Conditions: Pancreatitis
Interventions: Sodium Phosphate, Potassium Phosphate; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Photon-counting CT, Energy-integrating CT; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions: Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Molgramostim, Placebo, Molgramostim Open-label; Drug
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 25 Years
Enrollment: 5,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 203
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more

Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging; Procedure · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more

Conditions: Sickle Cell Disease
Interventions: Red Blood Cell, Standard of care; Biological · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more

About this Duke University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Duke University Medical Center in Durham, NC as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Duke University Medical Center

Filter and sort this campus

Live official records

Duke APOL1 Research Biorepository

Low Intensity Focused Ultrasound Stimulation in Stroke Patients - Parameter Optimization

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Phosphate in Acute Pancreatitis

Photon-counting CT in Chest Imaging

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

About this Duke University Medical Center institution page